Todd C. Davis - 09 Jun 2023 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
By: /s/ Andrew Reardon For: Todd C. Davis
Issuer symbol
LGND
Transactions as of
09 Jun 2023
Transactions value $
-$30,979
Form type
4
Date filed
13 Jun 2023, 18:52
Previous filing
27 Feb 2023
Next filing
25 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Tax liability -$31K -420 -0.6% $73.76 69.1K 09 Jun 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.
F2 The number reflected in Column 5 reconciles the total number of shares beneficially held following the transactions reported herein.